Drug Guidance for Subsidy 17/02/2025 Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy NRThe Ministry of Health’s Drug Advisory Committee has not recommended glofitamab for inclusio... See all × 17/02/2025 Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy NRThe Ministry of Health’s Drug Advisory Committee has not recommended glofitamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The decision was based on uncertain clinical effectiveness and unfavourable cost effectiveness of glofitamab compared with relevant comparators, and the unacceptable price-volume agreement proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for glofitamab are provided in the Annex.
Post Marketing Information PAC 04/10/2024 Important Safety Information for Patients receiving Columvi® (glofitamab): Patient Card
INTRAVENOUS Select a brand starting with the letter: C COLUMVI CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML [SIN16968P]